J Clin Oncol 36 (11): 1073-1079, 2018.[PUBMED Abstract] Treatment Option Overview for Metastatic Breast Cancer Metastatic HER2-Negative Hormone Receptor–Positive Breast CancerEndocrine therapy and cyclin-dependent kinase (CDK) inhibitor therapyMammalian target of rapamycin (mTOR) inhibitor therapy plus endocrine therapyAKT inhibitor therapyAlpelisib plus endocrine therapyElacestrantHDAC inhibitor therapyEndocrine therapy aloneSequencing therapy for hormone receptor–positive metastatic breast cancerSacituzumab govitecanChemotherapy Endocrine therapy and cyclin-dependent kinase (CDK) inhibitor therapy Mammalian target of rapamycin (mTOR) inhibitor therapy plus endocrine therapy AKT inhibitor therapy Alpelisib plus endocrine therapy Elacestrant HDAC inhibitor therapy Endocrine therapy alone Sequencing therapy for hormone receptor–positive metastatic breast cancer Sacituzumab govitecan Chemotherapy Metastatic HER2-Low Breast Cancer Metastatic Triple-Negative Breast CancerChemotherapy plus immunotherapySacituzumab govitecanPARP inhibitor therapyChemotherapyImmunotherapy monotherapy Chemotherapy plus immunotherapy Sacituzumab govitecan PARP inhibitor therapy Chemotherapy Immunotherapy monotherapy Metastatic HER2-Positive Breast CancerMonoclonal antibody therapyTrastuzumab deruxtecanMargetuximabTyrosine kinase inhibitor (TKI) therapymTOR inhibition Monoclonal antibody therapy Trastuzumab deruxtecan Margetuximab Tyrosine kinase inhibitor (TKI) therapy mTOR inhibition GermlineBRCA-Mutated Metastatic Breast CancerOlaparibTalazoparib Olaparib Talazoparib High Tumor Mutational Burden Breast CancerPembrolizumab Pembrolizumab Chemotherapy for Metastatic Breast CancerCapecitabine and fluorouracil dosingCardiac toxic effects with anthracyclines Capecitabine and fluorouracil dosing Cardiac toxic effects with anthracyclines Surgical Treatment for Metastatic Breast Cancer Radiation Therapy for Metastatic Breast Cancer Bone-Modifying Therapy for Metastatic Breast Cancer Current Clinical Trials Treatment of metastatic disease is palliative in intent.